729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors
Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A824-A824
10.1136/jitc-2023-sitc2023.0729